PPIs Negatively Impact Outcomes of Patients Treated With Capecitabine

PPIs Negatively Impact Outcomes of Patients Treated With Capecitabine
PPIs Negatively Impact Outcomes of Patients Treated With Capecitabine

Concomitant administration of proton pump inhibitors significantly and negatively impacted progression-free survival, overall survival, and disease control rate in patients with metastatic gastroesophageal cancer treated with capecitabine, a study published in JAMA Oncology has shown.1

Capecitabine is an oral cytotoxic agent commonly used across cancer subtypes, including breast cancer and gastrointestinal cancers. Because gastric acid suppressants, such as proton pump inhibitors (eg, omeprazole and pantropazole), affect the absorption of some oral medications, researchers sought to determine if proton pump inhibitors impair capecitabine efficacy.

For the study, investigators analyzed data from 545 patients with ERBB2/HER2-positive metastatic gastroesophageal cancer who participated in the phase 3 TRIO-013 trial, which evaluated the efficacy and safety of capetcitabine and oxaliplatin with or without lapatinib. Of those, 42.0% received concomitant proton pump inhibitors and were evenly distributed between treatment arms.

Results showed that among patients treated with capecitabine plus oxaliplatin, those who received proton pump inhibitors had a 55% higher risk of progression or death (hazard ratio [HR], 1.55; 95% CI, 1.29-1.81; P <.001) and a 34% higher risk of mortality (HR, 1.34; 95% CI, 1.06-1.62; P =.04) compared with those not treated with proton pump inhibitors.

In addition, patients treated with proton pump inhibitors had a disease control rate of 83% vs 72% for those not given proton pump inhibitors (P =.02).

After adjusting for confounding factors, study further demonstrated significantly poorer progression-free survival (HR, 1.68; 95% CI, 1.42-1.94; P <.001) and overall survival (HR, 1.41; 95% CI, 1.11-1.71; P =.001) in proton pump inhibitor-treated patients.

Researchers also found that concomitant administration with proton pump inhibitors had a lesser effect on progression-free survival and overall survival among those treated with lapatinib; however, investigators observed a significant difference in overall survival (HR, 1.38; 95% CI, 1.06-1.66; P =.03) in multivariate analysis.


1. Chu MP, Hecht JR, Slamon D, et al. Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013/LOGiC randomized clinical trial. JAMA Oncol. 2016 Oct 13. doi: 10.1001/jamaoncol.2016.3358. [Epub ahead of print]

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs